RxDoctor Payments Data

Douglas Head, MD

Cardiovascular Disease · Murrells Inlet, SCNPI 1851383459

Payments from drug & device makers

$794in general payments, 2019–2025

Across 44 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$457
  • Novartis$59
  • Amgen$46
  • Boston Scientific$42
  • Johnson & Johnson$37
  • Cvrx, Inc.$36
  • plus $118 from 7 others

What the payments were for

  • Food & beverage$794100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$794 in reported general payments places this provider in the 20th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$171,022
Medicare patients
538
Services billed
2,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$244,594
XareltoRivaroxaban76$103,250
EntrestoSacubitril/Valsartan28$30,378
Repatha SureclickEvolocumab16$23,443
Metoprolol Succinate346$5,329
Flecainide Acetate89$4,280
Valsartan38$2,404
Losartan Potassium233$1,788
Irbesartan23$1,314
Dilt-XrDiltiazem Hcl30$1,282
Bumetanide19$988
Amlodipine Besylate161$882
Carvedilol106$879
Furosemide138$744
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$244,594175 claims
Johnson & JohnsonXarelto$37$103,25076 claims
NovartisEntresto$59$30,37828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Murrells Inlet

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →